Browse by Poster Presenter

Type here to filter the list

T
Tahara, Makoto

National Cancer Center Hospital East
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Makoto Tahara
Favorite
Tamborini, Elena

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Elena Tamborini
Favorite
Tamir, Shlomit
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Shlomit Tamir
Favorite
Tammela, Tuomas

MSKCC
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Tuomas Tammela
Favorite
Tan, Aik Choon

Moffitt Cancer Center and Research Institute
(P 177) GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
Aik Choon Tan
Favorite
Tanaka, Yasuhito

Nara Medical University
(P 181) MITOCHONDRIAL TRANSFER FROM MESENCHYMAL STEM CELSS MEDIATED BY HMGB1 COULD BE INVOLVED IN DRUG RESISTANCE IN OSTEOSARCOMA CELLS.
Yasuhito Tanaka
Favorite
Tanas, Munir

Holden Comprehensive Cancer Center
(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Munir Tanas
Favorite
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Munir Tanas
Favorite
Tan, Daniel S. W.

Division of Medical Oncology, National Cancer Centre Singapore, Duke-NUS Medical School
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Daniel S. W. Tan
Favorite
Tang, Cheuk Ho Gordon

Department of Clinical Oncology, Prince of Wales Hospital
(P 210) A LONGITUDINAL ANALYSIS OF PROGNOSTIC FACTORS IN CHINESE PATIENTS WITH RETROPERITONEAL LIPOSARCOMA
Cheuk Ho Gordon Tang
Favorite
Tang, Gordon C.H.

The Chinese University of Hong Kong
(P 186) PRECLINICAL STUDY OF DOXORUBICIN IN COMBINATION WITH PANOBINOSTAT IN XENOGRAFT MICE MODELS OF SOFT TISSUE SARCOMAS
Gordon C.H. Tang
Favorite
Tang, Xiaodong

Peking University People’s Hospital
(P 021) DISTINCT GENOMIC FEATURES BETWEEN OSTEOSARCOMAS FIRSTLY METASTASING TO BONE AND TO LUNG
Xiaodong Tang
Favorite
Tan, Heng

University of Miami
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Heng Tan
Favorite
Tao, Qian

The Chinese University of Hong Kong
(P 186) PRECLINICAL STUDY OF DOXORUBICIN IN COMBINATION WITH PANOBINOSTAT IN XENOGRAFT MICE MODELS OF SOFT TISSUE SARCOMAS
Qian Tao
Favorite
Tap, William

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
(P 04) EXPERT PANEL REVIEW OF THE PRO-AYA: PARTIENT-REPORTED OUTCOMES FOR ADOLESCENTS AND YOUNG ADULTS WITH CANCER
William Tap
Favorite
(P 066) CHARACTERISTICS OF PATIENTS RECEIVING PEXIDARTINIB IN THE REAL-WORLD SETTING: A CROSS-SECTIONAL SURVEY
William Tap
Favorite
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
William Tap
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
William Tap
Favorite
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
William Tap
Favorite
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
William Tap
Favorite
(P 307) ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
William Tap
Favorite
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
William Tap
Favorite
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
William Tap
Favorite
Taque, Sophie

CHU Rennes
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Sophie Taque
Favorite
Tarabichi, Maxime

Francis Crick Institute
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Maxime Tarabichi
Favorite
Tararykova, Anastasia

Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
(P 158) NEOADJUVANT COMBINATION OF DOXORUBICIN, CISPLATIN AND METHOTREXATE IN PATIENTS AGED 24-40 YEARS WITH OSTEOSARCOMA UNDER THE COVERAGE OF HEMODIALYSIS. AMAP2021-7-2. ONGOING TRIAL
Anastasia Tararykova
Favorite
Tasnim, Najifah

CanSaRCC, Princess Margaret Cancer Center, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Najifah Tasnim
Favorite
Tassan-Mangina, Marta

Humanitas University
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Marta Tassan-Mangina
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Marta Tassan-Mangina
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Marta Tassan-Mangina
Favorite
Tasse, Jordan

Rush University Medical Center
(P 294) PERCUTANEOUS STABILIZATION OF PATHOLOGIC FRACTURES OF THE PELVIS AND SACRUM
Jordan Tasse
Favorite
Tavanaie, Nasrin

University of California, Los Angeles
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Nasrin Tavanaie
Favorite
Teague, Destini

UT Southwestern
(P 035) RISK FACTORS FOR BONY METASTASES IN PEDIATRIC OSTEOSARCOMA PATIENTS
Destini Teague
Favorite
Tebon, Peyton

UCLA
(P 183) OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY
Peyton Tebon
Favorite
Tebon, Peyton

University of California, Los Angeles
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Peyton Tebon
Favorite
Teh, Bin Tean

National Cancer Centre Singapore
(P 174) ESTABLISHMENT AND CHARACTERIZATION OF A PATIENT-DERIVED SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA CELL LINE MODEL
Bin Tean Teh
Favorite
Tellez, Walter

Sarcoma Oncology Research Center
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Walter Tellez
Favorite
Tepper, Sarah

Rush University Medical Center
(P 075) EXAMINING PATIENT PERSPECTIVES ON SARCOMA SURVEILLANCE: THE SARCOMA SURVEILLANCE SURVEY
Sarah Tepper
Favorite
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Sarah Tepper
Favorite
(P 086) RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Sarah Tepper
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Sarah Tepper
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Sarah Tepper
Favorite
(P 283) HIP ARTHROPLASTY OUTCOMES IN METASTATIC BONE DISEASE
Sarah Tepper
Favorite
Terlizzi, Mario

Department of Radiotherapy, Institut Bergonié
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Mario Terlizzi
Favorite
Terracciano, Luigi

Humanitas University
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Luigi Terracciano
Favorite
Teterycz, Pawel

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 168) SYSTEMIC INFLAMMATION INDEX (SII) AS INDEPENDENT PREDICTIVE FACTOR IN PATIENTS WITH L-SARCOMA TREATED WITH TRABECTEDIN - ANALYSIS OF REAL-WORLD EVIDENCE FROM A REFERENCE CENTER
Pawel Teterycz
Favorite
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Pawel Teterycz
Favorite
Teterycz, Paweł

Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie National Research Institute of Oncology
(P 166) SARCOMA BRAIN METASTASES: EXPERIENCE AT A SINGLE INSTITUTION
Paweł Teterycz
Favorite
Teuber, Alina

Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Alina Teuber
Favorite
Teufel, Michael

Boehringer Ingelheim Pharmaceuticals, Inc.
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Michael Teufel
Favorite
(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Michael Teufel
Favorite
Thayaparan, Thivyan

Director, Scientific Strategy, GSK
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Thivyan Thayaparan
Favorite
Thebaud, Estelle

CHU Nantes
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Estelle Thebaud
Favorite
Thomas, Stephanie

Cleveland Clinic
(P 311) VIRTUAL VISITS FOR SARCOMAS AND OTHER RARE CANCERS INCLUDING DESMOIDS: THE EVOLUTION OF INFORMATION AND EDUCATIONAL OPPORTUNITIES TO IMPOVE HEALTH: 2017-2022
Stephanie Thomas
Favorite
Thornton, Shelby

University of British Columbia
(P 129) MATURE DENDRITIC CELLS ON TISSUE MICROARRAY CORES CORRELATE WITH THE PRESENCE OF ADJACENT TERTIARY LYMPHOID STRUCTURES IN EPITHELIOID SARCOMA
Shelby Thornton
Favorite
Thorpe, Steven

University of California, Davis/Orthopaedic Surgery
(P 175) FIBRIN-ALGINATE INTERPENETRATING NETWORK HYDROGELS AS BIOMIMETIC PLATFORMS TO STUDY OSTEOSARCOMA
Steven Thorpe
Favorite
Thrussell, Imogen

The Institute of Cancer Research
(P 061) UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Imogen Thrussell
Favorite
Thway, Khin

The Royal Marsden NHS Foundation Trust
(P 061) UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Khin Thway
Favorite
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Khin Thway
Favorite
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Khin Thway
Favorite
Timmermann, Beate

Clinic for Particle Therapy, West German Proton Beam Centre, University Hospital Essen, West German Cancer Centre, German Cancer Research Centre (DKTK)
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Beate Timmermann
Favorite
Timmermans, Iris

Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Iris Timmermans
Favorite
Tinè, Gabriele

Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Gabriele Tinè
Favorite
Tinoco, Gabriel

The Ohio State University Comprehensive Cancer Center
(P 200) CLINICAL CHARACTERISTICS, PATTERNS OF CARE, AND TREATMENT OUTCOMES OF RADIATION-ASSOCIATED SARCOMAS
Gabriel Tinoco
Favorite
(P 259) ASSOCIATION BETWEEN AREA DEPRIVATION INDEX AND INITIAL TREATMENT AMONG PATIENTS WITH DESMOID TUMORS
Gabriel Tinoco
Favorite
Tirabosco, Roberto

Royal National Orthopaedic Hospital NHS Trust
(P 011) TACKLE A RARE SARCOMA THROUGH A COLLABORATIVE APPROACH
Roberto Tirabosco
Favorite
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Roberto Tirabosco
Favorite
Tirode, Franck

CANCER RESEARCH CENTER OF LYON / CENTER LEON BERARD
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Franck Tirode
Favorite
Tirtei, Elisa

Paediatric Onco-Haematology Division, Regina Margherita Children’s Hospital, City of Health and Science of Turin and Department of Public Health and Paediatrics, University of Turin
(P 029) MOLECULAR CHARACTERIZATION OF OSTEOSARCOMA AND EWING SARCOMA IN PEDIATRIC PATIENTS REVEALS NOVEL RNA-BASED INTERVENTION POINTS.
Elisa Tirtei
Favorite
Tisherman, Robert

University of Pittsburgh Medical Center
(P 087) RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Robert Tisherman
Favorite
Todd, Kevin

Division of Pediatric Hematology-Oncology, Children's Hospital of the Kings Daughter, Norfolk, Virginia, USA
(P 118) SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA
Kevin Todd
Favorite
Toh, Tan Boon

The N.1 Institute for Health, National University of Singapore
(P 196) THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Tan Boon Toh
Favorite
Toki, Shunichi

Department of Orthopedics Institute of Biomedical Sciences
(P 275) ASSESSMENT OF SURGICAL MARGIN CLASSIFICATION FOR SOFT TISSUE SARCOMA: DEFINITIONS OF ADEQUATE MARGINS SYSTEM FOR PLANNING AND EVALUATION
Shunichi Toki
Favorite
Tokura, Momoko

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Momoko Tokura
Favorite
Tolcher, Anthony

NEXT Oncology
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Anthony Tolcher
Favorite
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Anthony Tolcher
Favorite
Tomberger, Martina

Center for Biomarker Research in Medicine (CBmed)
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Martina Tomberger
Favorite
Tong, Cina SL

Department of Imaging and Interventional Radiology, Prince of Wales Hospital
(P 210) A LONGITUDINAL ANALYSIS OF PROGNOSTIC FACTORS IN CHINESE PATIENTS WITH RETROPERITONEAL LIPOSARCOMA
Cina SL Tong
Favorite
Tonini, Giuseppe

Campus Bio-Medico University of Rome
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Giuseppe Tonini
Favorite
Topal, Baki

UZ Leuven
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Baki Topal
Favorite
Torregrosa, Begoña

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Begoña Torregrosa
Favorite
Torres-Mozas, Pablo

Hospital Universitario de Jaén
(P 083) PERFORMANCE OF THE MESENCHYMAL TUMOR COMMITTEE IN A SMALL HOSPITAL IN SOUTHERN SPAIN
Pablo Torres-Mozas
Favorite
Tortorelli, Ilaria

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Ilaria Tortorelli
Favorite
Tortoreto, Monica

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Monica Tortoreto
Favorite
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Monica Tortoreto
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Monica Tortoreto
Favorite
Toulmonde, Maud

Department of Medical Oncology, Institut Bergonié
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Maud Toulmonde
Favorite
Town, Ajia

OHSU Knight Cancer Institute
(P 121) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES IN PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Ajia Town
Favorite
Traast-Kooistra, Jolanda

LUMC
(P 230) CHARACTERIZING TISSUE-BASED CHANGES DURING AND AFTER RADIOTHERAPY IN MYXOID LIPOSARCOMAS IN THE DOREMY TRIAL
Jolanda Traast-Kooistra
Favorite
Treckmann, Jürgen

Department of Visceral Surgery, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Jürgen Treckmann
Favorite
Trent, Jonathan

University of Miami/Sylvester Comprehensive Cancer Center
(P 07) HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Jonathan Trent
Favorite
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Jonathan Trent
Favorite
(P 096) AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Jonathan Trent
Favorite
(P 098) COMBINATION THERAPY WITH IMATINIB AND PAC-1 INDUCES TREATMENT SYNERGISM IN GASTROINTESTINAL STROMAL TUMORS
Jonathan Trent
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Jonathan Trent
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Jonathan Trent
Favorite
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Jonathan Trent
Favorite
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Jonathan Trent
Favorite
Trimm, Conner

UC San Diego
(P 279) CEMENT AUGMENTATION WITH CEPHALLOMEDUALLARY FIXATION OF PRIMARY AND METASTATIC LESIONS OF THE PROXIMAL FEMUR.
Conner Trimm
Favorite
Trout, Andrew

Cincinnati Children's Hospital Medical Center
(P 118) SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA
Andrew Trout
Favorite
Trovillion, Erin

Atrium Health - Levine Children's Hospital
(P 246) PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Erin Trovillion
Favorite
Trowbridge, Melissa

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Melissa Trowbridge
Favorite
Trucco, Matteo

Cleveland Clinic Children's
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Matteo Trucco
Favorite
(P 249) SARCOMA GENE FUSION BREAKPOINTS: NON-RANDOM EVENT PATTERNS IN SARCOMAS WITH GENE FUSIONS INCLUDING EWING SARCOMA, DSRCT, RHABDOMYOSARCOMA, SYNOVIAL SARCOMA, CCNB3-BCOR, AND CIC-DUX
Matteo Trucco
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Matteo Trucco
Favorite
(P 311) VIRTUAL VISITS FOR SARCOMAS AND OTHER RARE CANCERS INCLUDING DESMOIDS: THE EVOLUTION OF INFORMATION AND EDUCATIONAL OPPORTUNITIES TO IMPOVE HEALTH: 2017-2022
Matteo Trucco
Favorite
Tsagkozis, Panagiotis

Musculoskeletal Tumor Service, Karolinska University Hospital, Stockholm, Sweden
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Panagiotis Tsagkozis
Favorite
Tsagkozis, Panagiotos

Karolinska University Hospital
(P 242) LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Panagiotos Tsagkozis
Favorite
Tsai, Harrison
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Harrison Tsai
Favorite
Tseng, William

City of Hope National Medical Center
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
William Tseng
Favorite
Tse, Teresa

Department of Clinical Oncology, The Chinese University of Hong Kong
(P 186) PRECLINICAL STUDY OF DOXORUBICIN IN COMBINATION WITH PANOBINOSTAT IN XENOGRAFT MICE MODELS OF SOFT TISSUE SARCOMAS
Teresa Tse
Favorite
(P 210) A LONGITUDINAL ANALYSIS OF PROGNOSTIC FACTORS IN CHINESE PATIENTS WITH RETROPERITONEAL LIPOSARCOMA
Teresa Tse
Favorite
Tsimicalis, Argerie

McGill University
(P 064) A SYSTEMATIC REVIEW OF PATIENT-REPORTED OUTCOMES USED TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN SOFT-TISSUE SARCOMA
Argerie Tsimicalis
Favorite
(P 082) PATIENT-REPORTED OUTCOME MEASURES TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH SOFT-TISSUE SARCOMA: A SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT-REPORTED OUTCOMES
Argerie Tsimicalis
Favorite
(P 092) THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Argerie Tsimicalis
Favorite
Tsoi, Kim

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto; Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto
(P 059) SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Kim Tsoi
Favorite
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Kim Tsoi
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Kim Tsoi
Favorite
(P 233) DETERMINING THE CONTRIBUTIONS OF PD-L1 AND STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Kim Tsoi
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Kim Tsoi
Favorite
(P 304) SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Kim Tsoi
Favorite
Tsuchie, Hiroyuki

Akita University Graduate School of Medicine
(P 084) PROGNOSTIC FACTORS IN PATIENTS WITH DISTANT SOFT TISSUE METASTASIS OF CARCINOMA
Hiroyuki Tsuchie
Favorite
(P 285) IMPACT OF ACRIDINE ORANGE IN PATIENTS WITH LOCAL RECURRENT SOFT TISSUE SARCOMA
Hiroyuki Tsuchie
Favorite
Tsukamoto, Shinji

Nara Medical University
(P 181) MITOCHONDRIAL TRANSFER FROM MESENCHYMAL STEM CELSS MEDIATED BY HMGB1 COULD BE INVOLVED IN DRUG RESISTANCE IN OSTEOSARCOMA CELLS.
Shinji Tsukamoto
Favorite
Tufino, Carolina

University of Pittsburgh
(P 036) STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Carolina Tufino
Favorite
Tu, Janet

The University of Texas MD Anderson Cancer Center
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Janet Tu
Favorite
Tumminello, Brad

SpringWorks Therapeutics
(P 260) BURDEN OF ILLNESS OF DESMOID TUMORS
Brad Tumminello
Favorite
Tuohy, Joanne

Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Joanne Tuohy
Favorite
Turcotte, Robert

Division of Orthopaedic Surgery, McGill University
(P 022) EZHIP ECTOPIC EXPRESSION AND ITS ROLE IN OSTEOSARCOMA PATHOGENESIS
Robert Turcotte
Favorite
(P 030) OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Robert Turcotte
Favorite
turcotte, robert

McGill University Health Centre
(P 064) A SYSTEMATIC REVIEW OF PATIENT-REPORTED OUTCOMES USED TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN SOFT-TISSUE SARCOMA
robert turcotte
Favorite
(P 082) PATIENT-REPORTED OUTCOME MEASURES TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH SOFT-TISSUE SARCOMA: A SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT-REPORTED OUTCOMES
robert turcotte
Favorite
(P 092) THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
robert turcotte
Favorite
Turpin, Brian

Cancer and Blood Diseases Institute/ Cincinnati Children's Hospital Medical Center
(P 118) SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA
Brian Turpin
Favorite
Tu, Zheng Jin

Cleveland Clinic
(P 249) SARCOMA GENE FUSION BREAKPOINTS: NON-RANDOM EVENT PATTERNS IN SARCOMAS WITH GENE FUSIONS INCLUDING EWING SARCOMA, DSRCT, RHABDOMYOSARCOMA, SYNOVIAL SARCOMA, CCNB3-BCOR, AND CIC-DUX
Zheng Jin Tu
Favorite
Tysarowski, Andrzej

Cancer Molecular and Genetic Diagnostics Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Andrzej Tysarowski
Favorite
Tzanis, Dimitri

Department of Surgical Oncology, Institut Curie
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Dimitri Tzanis
Favorite
Tzelnick, Sharon

Princess Margaret Cancer Center, University of Toronto
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Sharon Tzelnick
Favorite